Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 5
2009 2
2010 7
2011 3
2012 6
2013 5
2014 3
2015 12
2016 12
2017 7
2018 5
2019 10
2020 11
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Results by year
Filters applied: . Clear all
Page 1
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
Lévy Y, Lelièvre JD, Assoumou L, Aznar E, Pulido F, Tambussi G, Crespo M, Meybeck A, Molina JM, Delaugerre C, Izopet J, Peytavin G, Cardon F, Diallo A, Lancar R, Béniguel L, Costagliola D. Lévy Y, et al. Among authors: assoumou l. Ann Intern Med. 2020 Mar 3;172(5):297-305. doi: 10.7326/M19-2133. Epub 2020 Feb 11. Ann Intern Med. 2020. PMID: 32040959 Clinical Trial.
Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
Tebano G, Soulié C, Schneider L, Blanc C, Agher R, Seang S, Valantin MA, Palich R, Tubiana R, Peytavin G, Marcelin AG, Assoumou L, Katlama C. Tebano G, et al. Among authors: assoumou l. J Antimicrob Chemother. 2020 Mar 1;75(3):675-680. doi: 10.1093/jac/dkz478. J Antimicrob Chemother. 2020. PMID: 31800056
Piloting a surveillance system for HIV drug resistance in the European Union.
van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML, Descamps D, Dauwe K, Fonager J, Hauser A, Lunar M, Mezei M, Neary M, Poljak M, van Sighem A, Verhofstede C, Amato-Gauci AJ, Broberg EK. van de Laar MJ, et al. Among authors: assoumou l. Euro Surveill. 2019 May;24(19):1800390. doi: 10.2807/1560-7917.ES.2019.24.19.1800390. Euro Surveill. 2019. PMID: 31088600 Free PMC article.
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin AG; ANRS-163 ETRAL study group. Soulie C, et al. Among authors: assoumou l. J Antimicrob Chemother. 2020 Jul 1;75(7):1943-1949. doi: 10.1093/jac/dkaa090. J Antimicrob Chemother. 2020. PMID: 32259255
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
Assoumou L, Racine C, Fellahi S, Lamaziere A, Farabos D, Beniguel L, Bastard JP, Feve B, Gibowski S, Katlama C, Costagliola D, Capeau J. Assoumou L, et al. AIDS. 2020 Oct 1;34(12):1859-1862. doi: 10.1097/QAD.0000000000002644. AIDS. 2020. PMID: 32773470
Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial).
Abe E, Assoumou L, de Truchis P, Amat K, Gibowski S, Gras G, Bellet J, Saillard J, Katlama C, Costagliola D, Girard PM, Landman R, Alvarez JC. Abe E, et al. Among authors: assoumou l. Br J Clin Pharmacol. 2020 Oct 3. doi: 10.1111/bcp.14586. Online ahead of print. Br J Clin Pharmacol. 2020. PMID: 33010058
Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing.
Raymond S, Delaugerre C, Nicot F, Assoumou L, Lancar R, Beniguel L, Izopet J; ANRS 146 OPTIMAL study group. Raymond S, et al. Among authors: assoumou l. AIDS. 2018 Oct 23;32(16):2429-2431. doi: 10.1097/QAD.0000000000001976. AIDS. 2018. PMID: 30102658
No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection.
Abdi B, Nguyen T, Brouillet S, Desire N, Sayon S, Wirden M, Jary A, Achaz G, Assoumou L, Palich R, Simon A, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG, Soulie C. Abdi B, et al. Among authors: assoumou l. AIDS. 2020 Oct 1;34(12):1745-1753. doi: 10.1097/QAD.0000000000002629. AIDS. 2020. PMID: 32694418
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.
Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D. Katlama C, et al. Among authors: assoumou l. J Antimicrob Chemother. 2020 Dec 1;75(12):3699-3700. doi: 10.1093/jac/dkaa341. J Antimicrob Chemother. 2020. PMID: 32954404 No abstract available.
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML; AC43 ANRS Resistance Group. Visseaux B, et al. Among authors: assoumou l. J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404. J Antimicrob Chemother. 2020. PMID: 31641777
86 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback